SS-31 (Elamipretide): Mitochondrial Peptide, Cardiolipin & Aging Research

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is SS-31?

SS-31, also known by its pharmaceutical name elamipretide (formerly Bendavia and MTP-131), is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt represents 2,6-dimethyltyrosine. It belongs to the Szeto-Schiller (SS) peptide series, developed by Dr. Hazel Szeto and Dr. Peter Bhatt Schiller at Weill Cornell Medical College, designed to selectively target and concentrate within the inner mitochondrial membrane.

What makes SS-31 uniquely significant in mitochondrial research is its mechanism of action: it specifically interacts with cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane that is essential for the function of the electron transport chain (ETC). Cardiolipin damage and depletion are increasingly recognized as central events in mitochondrial dysfunction — and mitochondrial dysfunction is considered one of the primary hallmarks of aging by the current scientific framework.

SS-31 has undergone extensive clinical development by Stealth BioTherapeutics (now Larimar Therapeutics), with phase I through III clinical trials in heart failure, mitochondrial myopathy (Barth syndrome), primary mitochondrial myopathy, and age-related macular degeneration. This clinical development program — though it has faced setbacks — has generated substantial human pharmacokinetic, safety, and efficacy data that exceeds what is available for most research peptides.

Mitochondrial Dysfunction: The Central Problem

Understanding SS-31 requires appreciating why mitochondrial dysfunction matters so broadly across disease and aging:

• Energy production — Mitochondria generate approximately 90% of cellular ATP through oxidative phosphorylation (OXPHOS). The electron transport chain, embedded in the inner mitochondrial membrane, comprises complexes I–IV and ATP synthase (complex V).
• Cardiolipin’s critical role — Cardiolipin constitutes approximately 20% of the inner mitochondrial membrane’s lipid composition and is required for the proper function of complexes I, III, IV, and V. It stabilizes the supercomplexes (respirasomes) that enable efficient electron transfer and prevents electron leak that generates reactive oxygen species (ROS).
• The vicious cycle — When cardiolipin is damaged (typically by ROS), electron transport becomes less efficient, generating more ROS, which damages more cardiolipin. This vicious cycle of mitochondrial ROS production → cardiolipin damage → further dysfunction is considered a central driver of cellular aging and mitochondrial disease.
• Broad disease relevance — Mitochondrial dysfunction has been implicated in heart failure, neurodegeneration (Alzheimer’s, Parkinson’s), kidney disease, diabetes, sarcopenia, and the aging process itself.

How SS-31 Works: Mechanism of Action

SS-31’s mechanism is distinct from conventional antioxidants and represents a fundamentally different approach to addressing mitochondrial dysfunction:

• Selective mitochondrial targeting — The alternating aromatic-cationic motif of SS-31 (D-Arg/Lys provide positive charge; Dmt/Phe provide aromatic character) drives its rapid and selective concentration in the inner mitochondrial membrane, independent of mitochondrial membrane potential. This is a critical distinction — many mitochondrial-targeted compounds rely on membrane potential for accumulation and therefore fail in dysfunctional mitochondria where membrane potential is compromised.
• Cardiolipin interaction — SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, stabilizing the phospholipid’s structure and protecting it from oxidative damage and peroxidation. This interaction does not alter cardiolipin’s essential functions but rather preserves them under conditions of oxidative stress.
• Electron transport chain optimization — By stabilizing cardiolipin, SS-31 preserves the structural integrity of ETC supercomplexes, maintaining efficient electron transfer and reducing electron leak from complexes I and III. The result is improved ATP production per unit of oxygen consumed and reduced ROS generation — essentially improving mitochondrial efficiency.
• ROS reduction at the source — Unlike conventional antioxidants that scavenge ROS after they are produced, SS-31 reduces ROS generation at its source by preventing the electron leak that creates superoxide. This upstream mechanism is considered more effective than downstream scavenging, which must compete with the rapid reaction rates of ROS with biological targets.
• Cytochrome c interaction — Research has shown that SS-31 modulates the interaction between cytochrome c and cardiolipin. Normally, cytochrome c functions as an electron carrier in the ETC. Under oxidative stress, cytochrome c gains peroxidase activity and oxidizes cardiolipin — contributing to the vicious cycle. SS-31 inhibits this peroxidase activity, maintaining cytochrome c in its electron carrier role.
• Mitochondrial permeability transition pore (mPTP) inhibition — SS-31 has been shown to inhibit the opening of the mPTP, a channel whose opening during ischemia-reperfusion or calcium overload leads to mitochondrial swelling and cell death. This anti-permeability transition effect contributes to SS-31’s documented cytoprotective properties.

Cardiac Research

Heart Failure Studies

Heart failure is characterized by severe mitochondrial dysfunction in cardiomyocytes, with documented cardiolipin depletion, reduced ETC efficiency, and increased oxidative stress. SS-31 has been extensively studied in this context:

• In canine and rodent heart failure models, SS-31 improved left ventricular ejection fraction, reduced end-diastolic pressure, and enhanced myocardial energetics
• Restored cardiolipin content and ETC supercomplex organization in failing heart tissue
• Reduced myocardial fibrosis and inflammatory markers

EMBRACE Clinical Trials

Stealth BioTherapeutics conducted the EMBRACE clinical trial program evaluating elamipretide in heart failure with reduced ejection fraction (HFrEF):

• EMBRACE-STEMI — Phase II trial in patients with ST-elevation myocardial infarction (heart attack). Intravenous elamipretide administered during percutaneous coronary intervention showed trends toward reduced infarct size in some subgroup analyses.
• Phase II HFrEF trial — 36 patients with HFrEF received elamipretide subcutaneously for 4 weeks. The treatment was associated with improvements in left ventricular end-systolic and end-diastolic volumes on cardiac MRI, suggesting favorable cardiac remodeling.

Ischemia-Reperfusion Injury

Ischemia-reperfusion (I/R) injury — the paradoxical tissue damage that occurs when blood flow is restored after ischemia — is a major clinical problem in heart attack, stroke, and organ transplantation. SS-31 has consistently reduced I/R injury in preclinical models across multiple organs, including heart, kidney, and brain. The mechanism involves preservation of mitochondrial function during ischemia and prevention of the ROS burst that occurs upon reperfusion.

Barth Syndrome Research

Barth syndrome is a rare genetic mitochondrial disorder caused by mutations in the tafazzin gene, which encodes the enzyme responsible for cardiolipin remodeling. Patients with Barth syndrome have abnormal cardiolipin composition, leading to severe cardiomyopathy, skeletal muscle weakness, and neutropenia. This disease represents the most direct clinical validation of the cardiolipin-targeting hypothesis.

The TAZPOWER clinical trial evaluated elamipretide in patients with Barth syndrome and reported improvements in the 6-minute walk test and other functional endpoints, with sustained benefit observed in the open-label extension. The trial results supported the mechanistic hypothesis that stabilizing cardiolipin interactions can produce clinical benefit in a disease defined by cardiolipin dysfunction.

Aging Research

The Mitochondrial Theory of Aging

SS-31 is of particular interest in aging research because it targets a core mechanism — mitochondrial dysfunction — that is listed among the hallmarks of aging. Age-related changes in mitochondria include reduced cardiolipin content, decreased ETC efficiency, increased ROS production, and accumulation of mitochondrial DNA mutations. SS-31 directly addresses several of these changes.

Preclinical Aging Studies

In aged animal models, SS-31 administration has been associated with:

• Restored mitochondrial energetics in skeletal muscle, with improved ATP production approaching levels seen in young animals
• Reversal of age-related changes in vascular endothelial function
• Improved cardiac diastolic function in aged mice (a hallmark of cardiac aging)
• Enhanced exercise tolerance and skeletal muscle performance
• Reduced oxidative stress markers in multiple tissues
• Improved insulin sensitivity in aged models

A notable 2018 study published in Aging Cell demonstrated that 8 weeks of SS-31 treatment reversed age-related mitochondrial dysfunction in old mice to levels comparable to young controls — specifically, cardiolipin content, ETC complex activity, and ATP production were restored to near-youthful levels in treated aged animals.

Renal Aging

Kidney function declines with age due in part to mitochondrial dysfunction in renal tubular epithelial cells. SS-31 has been investigated in models of age-related kidney decline and acute kidney injury (AKI), with studies reporting preservation of renal function, reduced tubular cell apoptosis, and improved mitochondrial morphology and function in treated animals.

Neurodegenerative Disease Research

Mitochondrial dysfunction is a prominent feature of neurodegenerative diseases. SS-31 has been investigated in models of:

• Alzheimer’s disease — Reduced mitochondrial dysfunction markers, improved synaptic mitochondrial function, and enhanced cognitive performance in transgenic AD mouse models
• Parkinson’s disease — Protection of dopaminergic neurons in MPTP and rotenone models of parkinsonism, with preserved mitochondrial complex I activity
• Amyotrophic lateral sclerosis (ALS) — Improved motor neuron survival and delayed disease progression in SOD1 mutant mouse models

Age-Related Macular Degeneration

The retinal pigment epithelium (RPE) is one of the most metabolically active tissues in the body, with high mitochondrial density and oxygen consumption. Age-related macular degeneration (AMD) involves RPE mitochondrial dysfunction, cardiolipin abnormalities, and oxidative damage. Clinical trials have evaluated topical and subcutaneous elamipretide for AMD, with the ReCLAIM study program reporting mixed results — some improvements in visual function parameters in subgroup analyses but failure to meet primary endpoints in the overall population.

Dosing in Research and Clinical Studies

Context	Dose	Route	Duration
Phase II HFrEF	4 mg/day	Subcutaneous	4 weeks
EMBRACE-STEMI	0.05 mg/kg/hr	Intravenous	1 hour during PCI
Barth syndrome (TAZPOWER)	40 mg/day	Subcutaneous	12 weeks + OLE
Rodent aging studies	3 mg/kg/day	Subcutaneous	8 weeks
I/R models	2–5 mg/kg	IV or IP	Single dose pre-ischemia
Cell culture	1–100 nM	Culture medium	1–24 hours

Reconstitution and Handling

• Storage — Lyophilized SS-31 at -20°C, protected from light and moisture
• Reconstitution — Reconstitute with sterile bacteriostatic water. SS-31 is water-soluble due to its cationic amino acids.
• Stability — Reconstituted solution stable approximately 14–21 days at 2–8°C. The D-amino acid (D-Arg) and modified amino acid (Dmt) provide enhanced proteolytic resistance.
• Note — The Dmt residue provides antioxidant properties to the peptide itself, contributing to solution stability. However, minimize exposure to strong oxidizing conditions.

Safety Profile

SS-31/elamipretide has accumulated substantial human safety data from its clinical trial program:

• Well-tolerated at clinical doses — No dose-limiting toxicities identified in phase I dose-escalation studies
• Most common adverse effect — Injection site reactions (subcutaneous route) — mild and transient
• No significant organ toxicity — Hepatic, renal, and hematological safety parameters remained stable across clinical trials
• No immunogenicity — No anti-drug antibodies detected in clinical subjects
• Favorable therapeutic window — SS-31 concentrates in mitochondria at concentrations ~1,000-fold higher than cytoplasmic levels, enabling efficacy at low systemic doses

Current Limitations and Future Directions

• Mixed clinical trial results — While preclinical data has been consistently strong, clinical trials have produced mixed results, with some failing to meet primary endpoints. This preclinical-to-clinical translation gap is a significant challenge.
• Patient selection — Identifying patients with the specific mitochondrial dysfunction phenotype most likely to respond to SS-31 may be key to improving clinical trial outcomes.
• Biomarker development — Validated biomarkers of cardiolipin integrity and mitochondrial efficiency are needed to guide patient selection and monitor treatment response.
• Chronic dosing optimization — Optimal treatment duration and dosing schedules for chronic conditions (aging, heart failure) are not yet established.
• Combination approaches — SS-31 combined with other mitochondrial-targeted interventions (NAD+ precursors, MOTS-c, exercise) represents an unexplored research frontier.

Summary

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane, optimizing electron transport chain function and reducing ROS generation at its source. With extensive preclinical data across cardiac, renal, neurological, and aging models, plus substantial clinical trial experience including phase II/III studies, SS-31 represents one of the most advanced compounds targeting the mitochondrial dysfunction hallmark of aging. While clinical results have been mixed, the mechanistic rationale — validated by the Barth syndrome program — remains compelling, and SS-31 continues to be a cornerstone compound in mitochondrial biology and aging research.

View SS-31 (Elamipretide) in our research catalog. Related mitochondrial research: MOTS-c and NAD+.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Russo et al.	2025	Review	Elamipretide: structure, mechanism of action, and therapeutic potential	PMC11816484
Dai et al.	2020	In Vivo	Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice	PMC7377906
Siegel et al.	2019	In Vivo	Improving mitochondrial function with SS-31 reverses age-related redox stress	PMC6588449
Birk et al.	2020	Proteomics	Mitochondrial protein interaction landscape of SS-31	PMC7334473
Mitchell et al.	2022	In Vivo	Long-term treatment with elamipretide enhances healthy aging phenotypes in mice	PMC9562127
Sweetwyne et al.	2017	In Vivo	SS-31 improves glomerular architecture in mice of advanced age	PMC5392164
Szeto	2022	Review	SS-31, a mitochondria-targeting peptide, ameliorates kidney disease	PMC9192202
Campbell et al.	2025	In Vivo	Elamipretide improves cardiac and skeletal muscle function during aging	PMC12151887

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.